Recently, the American Society of Clinical Oncology (ASCO) provided a new recommendation for the use of alpelisib, an orally bioavailable, α-specific phosphoinositide 3-kinase (PI3K) inhibitor, in the therapy of postmenopausal patients with HR+, HER2−, PIK3CA-mutated BC [9], which rekindled interest in the PIK3CA mutation as an eligible treatment selection biomarker; although this is based on data of the western population [10,11]. Here, ERBB2 is linked to breast cancer.